On this page
- Antiretroviral, HIV protease inhibitor
- Booster for protease inhibitors (atazanavir, darunavir, lopinavir, etc.) in HIV infection. Ritonavir should not be used alone.
Forms and strengths
- 25 mg and 100 mg tablets
Dosage depends on the administration schedule of the boosted protease inhibitor. The daily dose is administered once daily or in 2 divided doses.
- Child 14 to < 25 kg:
- 50 mg (two 25 mg tablets) 2 times daily, or
- 100 mg (four 25 mg tablets or one 100 mg tablet) once daily
- Child ≥ 25 kg and adult: 100 mg (one 100 mg tablet) once or 2 times daily
- Depending on the efficacy and tolerance of the boosted protease inhibitor and ritonavir.
Contra-indications, adverse effects, precautions
- Do not administer to patients with severe hepatic impairment.
- Administer with caution and monitor use in patients with haemophilia (increased bleeding) or mild to moderate hepatic impairment.
- The adverse effects of ritonavir as a booster are also dependent on the boosted protease inhibitor.
- May cause:
- gastrointestinal disturbances, fatigue, headache, dizziness, paraesthesia, joint and muscle pain, taste disturbances, hyperglycaemia, hyperlipidaemia, lipodystrophy, conduction disorders;
- pancreatitis, hepatic disorders, skin rash sometimes severe; in this event, stop treatment immediately.
- Ritonavir reduces the efficacy of implants and oral contraceptives
.: use injectable medroxyprogesterone or an intrauterine device. Only when combined with atazanavir, an oral contraceptive containing at least 30 micrograms of ethinylestradiol per tablet may also be used.
- Pregnancy: no contra-indication
- Take with meals.
- Tablets are not recommended in children < 14 kg.
- Also comes in fixed-dose combinations with other protease inhibitors (atazanavir, darunavir, lopinavir, etc.). Preferably use these formulations when available.
– Below 25 °C